Articles from Genetix Biotherapeutics Inc.

bluebird bio, Inc. today announced it has rebranded as Genetix Biotherapeutics Inc., returning to its foundational roots. Genetix, now strengthened both financially and operationally, is significantly better positioned to harness its decades of scientific innovation and extensive clinical data from hundreds of treated patients to more effectively deliver life-changing genetic therapies. The recently appointed Genetix management team, led by CEO David Meek, is committed to delivering on this mission. The company has three FDA-approved genetic therapies for patients living with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. These first-in-class, one-time administered therapies target the root cause of disease and can offer significant and lasting benefits to patients.